Qualifying children will have free access to Invitae's Comprehensive Deafness Panel, which assesses multiple genes linked to syndromic and non-syndromic deafness.
Sequencing-based newborn screening could not identify all children with metabolic disorders or hearing loss, but could interrogate a larger number of conditions.
In PLOS this week: CLCA2 expression linked to survival among African-American women with aggressive breast cancer, gene alterations linked to hearing loss, and more.
The pharmacogenetic test, which runs on a platform from British company Genedrive, will be tested in two neonatal intensive care units in Manchester and Liverpool.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.
In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.